Biomea Fusion Inc - Asset Resilience Ratio

Latest as of December 2023: 0.00%

Biomea Fusion Inc (BMEA) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check BMEA strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$0.00
Cash + Short-term Investments

Total Assets

$199.93 Million
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2020–2023)

This chart shows how Biomea Fusion Inc's Asset Resilience Ratio has changed over time. See BMEA net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Biomea Fusion Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Biomea Fusion Inc worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $0.00 0%
Total Liquid Assets $0.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: Biomea Fusion Inc maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company maintains a balanced mix of cash and short-term investments.

Biomea Fusion Inc Industry Peers by Asset Resilience Ratio

Compare Biomea Fusion Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Biotechnology -55.36%
Krystal Biotech Inc
NASDAQ:KRYS
Biotechnology 23.06%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for Biomea Fusion Inc (2020–2023)

The table below shows the annual Asset Resilience Ratio data for Biomea Fusion Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-12-31 0.00% $0.00 $199.93 Million --
2022-12-31 0.89% $1.15 Million $129.31 Million -14.07pp
2021-12-31 14.96% $27.78 Million $185.71 Million --
2020-12-31 0.00% $0.00 $62.53 Million --
pp = percentage points

About Biomea Fusion Inc

NASDAQ:BMEA USA Biotechnology
Market Cap
$86.76 Million
Market Cap Rank
#19864 Global
#4463 in USA
Share Price
$1.20
Change (1 day)
+3.45%
52-Week Range
$0.96 - $2.67
All Time High
$41.80
About

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase I… Read more